Stock Forecast

  NeuroBo Pharmaceuticals, Inc. ( NRBO) Stock. Should you Buy or Sell?    $ 0.28

-0.02 (-6.40 %)



NeuroBo Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol NRBO
Price $0.28
Beta -0.474
Volume Avg. $79.76 thousand
Market Cap $7.57 M
52 Week Range $0.247 - $4.289


NeuroBo Pharmaceuticals, Inc. opened the day at $0.28 which is -6.40 % on yesterday's close. NeuroBo Pharmaceuticals, Inc. has a 52 week high of $4.289 and 52 week low of $0.247, which is a difference of $4.042. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $7.57 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NeuroBo Pharmaceuticals, Inc. for $7.57 M, it would take 15 years to get your money back. NeuroBo Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




NeuroBo Pharmaceuticals, Inc. Stock Forecast - Is NeuroBo Pharmaceuticals, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreStrong Sell
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value


PE Ratio -0.295
Dividend Yiel 0.000
Net Profit Margin 0.000


Valuing NeuroBo Pharmaceuticals, Inc.


Price Book Value Ratio 0.833 Price To Book Ratio 0.833
Price To Sales Ratio 0.000 Price Earnings Ratio -0.295


How liquid is NeuroBo Pharmaceuticals, Inc.


Current Ratio 8.068
Quick Ratio 7.085


Debt


Debt Ratio 0.124 Debt Equity Ratio 0.141
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000



Latest news about NeuroBo Pharmaceuticals, Inc.


NeuroBo Pharmaceuticals Stock (NRBO): Why The Price Surged Today

The stock price of NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) increased by over 40% pre-market today. This is why it happened.

Date : 04/01/2022

Best Penny Stocks to Buy Right Now? Here's 3 For Your Watchlist in October

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?

Date : 14/10/2021

NRBO Stock: Why It Increased

The stock price of Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) increased by over 6% yesterday. This is why it happened.

Date : 14/10/2021

Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today

There's loads of hot penny stocks worth checking in on today and we're taking a look at what some of the top movers are doing! The post Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today appeared first on InvestorPlace.

Date : 13/10/2021

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced the closing of its previously announced registered direct offering of 4,307,693 shares of the Company's common stock, at a purchase price of $3.25 per share. In a concurrent private placement, the Company issued to the investors in the registered direct offering unregistered warrants to purchase up to 4,307,693 shares of the Company's common stock.

Date : 05/10/2021





About NeuroBo Pharmaceuticals, Inc.


CEO : Mr. Jeong Gu Kang
Sector : Healthcare
Industry : Biotechnology

Website : https://www.neurobopharma.com

Exchange : NASDAQ Capital Market

Description :

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.


My Newsletter

Sign Up For Updates & Newsletters